Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) – Pipeline Review, H2 2017’, provides in depth analysis on Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Central Nervous System, Dermatology, Gastrointestinal, Genetic Disorders, Infectious Disease and Musculoskeletal Disorders under development targeting Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98)

The report reviews Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects

The report assesses Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

4SC AG

Chipscreen Biosciences Ltd

Curis Inc

HitGen LTD

IRBM Science Park SpA

Medivir AB

Merck & Co Inc

Sigma-Tau SpA

Syndax Pharmaceuticals Inc

Zhejiang Hisun Pharmaceutical Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC

3.5.1.98) - Overview 7

Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC

3.5.1.98) - Therapeutics Development 8

Products under Development by Stage of Development 8

Products under Development by Therapy Area 9

Products under Development by Indication 10

Products under Development by Companies 15

Products under Development by Universities/Institutes 21

Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC

3.5.1.98) - Therapeutics Assessment 23

Assessment by Mechanism of Action 23

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC

3.5.1.98) - Companies Involved in Therapeutics Development 28

4SC AG 28

Chipscreen Biosciences Ltd 28

Curis Inc 29

HitGen LTD 30

IRBM Science Park SpA 30

Medivir AB 31

Merck & Co Inc 31

Sigma-Tau SpA 32

Syndax Pharmaceuticals Inc 32

Zhejiang Hisun Pharmaceutical Co Ltd 33

Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC

3.5.1.98) - Drug Profiles 35

4SC-202 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

CUDC-907 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Drug to Inhibit HDAC-3 for Oncology - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

entinostat - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

HG-3001 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

KDAC-0001 - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

largazole - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

remetinostat - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

Small Molecule to Inhibit HDAC1, HDAC3 and HDAC6 for Lung Adenocarcinoma - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

Small Molecules to Inhibit HDAC1, HDAC2 and HDAC3 for Oncology - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

ST-3595 - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

Synthetic Peptide to Inhibit HDAC for Prostate Cancer - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

tucidinostat - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

vorinostat - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC

3.5.1.98) - Dormant Products 71

Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC

3.5.1.98) - Product Development Milestones 73

Featured News & Press Releases 73

Jul 11, 2017: Preclinical Results Support Entinostat's Role in Targeting the Tumor Microenvironment to Enhance Immune Checkpoint Therapy 73

May 25, 2017: Curis Announces Presentation Related to CUDC-907 at 2017 ASCO Annual Meeting 73

May 17, 2017: Syndax Announces Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA (pembrolizumab) for the Treatment of Advanced Melanoma 74

May 16, 2017: Syndax Pharmaceuticals Announces Advancement of ENCORE 601 in Non-Small Cell Lung Cancer Patients with Disease Progression on or After PD-1 Therapies 75

Apr 20, 2017: Syndax Announces Entinostat Data to be Presented at the 2017 American Society of Clinical Oncology Annual Meeting 76

Apr 19, 2017: GNTbm to begin Phase III clinical trial in Taiwan of epigenetic regulator Chidamide for late-stage breast cancer 76

Apr 11, 2017: New mechanistic insights into 4SC-202’s epigenetic mode of action 77

Apr 07, 2017: Medivir announces positive data from the phase II study of remetinostat in patients with early-stage cutaneous T-cell lymphoma 78

Jan 05, 2017: Syndax Adds Global Pharmaceutical Business Veteran to Board of Directors 79

Nov 08, 2016: Syndax Pharmaceuticals to Present Data On Entinostat at the SITC 31st Annual Scientific Meeting 79

Jun 08, 2016: Curis Announces Oral Presentation of Clinical Data Update from the Phase 1 Study of CUDC-907 at the 21st Congress of the European Hematology Association 80

Jun 02, 2016: Curis Announces Presentations Related to CUDC-907 at 2016 ASCO Annual Meeting 80

May 18, 2016: Entinostat Data to be Highlighted at the American Society of Clinical Oncology 2016 Annual Meeting 81

Apr 11, 2016: Syndax Announces Entinostat Data to be Presented at the American Association for Cancer Research (AACR) 2016 Annual Meeting 82

Apr 11, 2016: Curis Announces Presentation of Preclinical Data for CUDC-907 at AACR Annual Meeting 83

Appendix 84

Methodology 84

Coverage 84

Secondary Research 84

Primary Research 84

Expert Panel Validation 84

Contact Us 84

Disclaimer 85

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Therapy Areas, H2 2017 9

Number of Products under Development by Indications, H2 2017 10

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 12

Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017 13

Number of Products under Development by Indications, H2 2017 (Contd..3), H2 2017 14

Number of Products under Development by Companies, H2 2017 15

Products under Development by Companies, H2 2017 16

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 17

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 18

Products under Development by Companies, H2 2017 (Contd..3), H2 2017 19

Products under Development by Companies, H2 2017 (Contd..4), H2 2017 20

Number of Products under Investigation by Universities/Institutes, H2 2017 21

Products under Investigation by Universities/Institutes, H2 2017 22

Number of Products by Stage and Mechanism of Actions, H2 2017 23

Number of Products by Stage and Route of Administration, H2 2017 25

Number of Products by Stage and Molecule Type, H2 2017 27

Pipeline by 4SC AG, H2 2017 28

Pipeline by Chipscreen Biosciences Ltd, H2 2017 29

Pipeline by Curis Inc, H2 2017 30

Pipeline by HitGen LTD, H2 2017 30

Pipeline by IRBM Science Park SpA, H2 2017 31

Pipeline by Medivir AB, H2 2017 31

Pipeline by Merck & Co Inc, H2 2017 32

Pipeline by Sigma-Tau SpA, H2 2017 32

Pipeline by Syndax Pharmaceuticals Inc, H2 2017 33

Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H2 2017 34

Dormant Products, H2 2017 71

Dormant Products, H2 2017 (Contd..1), H2 2017 72

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Therapy Areas, H2 2017 9

Number of Products under Development by Top 10 Indications, H2 2017 10

Number of Products by Stage and Mechanism of Actions, H2 2017 23

Number of Products by Routes of Administration, H2 2017 24

Number of Products by Stage and Routes of Administration, H2 2017 24

Number of Products by Molecule Types, H2 2017 26

Number of Products by Stage and Molecule Types, H2 2017 26

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports